Investigational drugs in development to prevent neuromyelitis optica relapses

Expert Opinion on Investigational Drugs

Volumn 27, Issue 3, 2018, Pages 265-271

  Paul, Friedemann ^a,b   Murphy, Olwen ^c   Pardo, Santiago ^c   Levy, Michael ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; Neuromyelitis optica; prognosis; risk assessment

Indexed keywords

ECULIZUMAB; MEDI-551; MONOCLONAL ANTIBODY; NEW DRUG; TOCILIZUMAB;

DRUG DESIGN; HUMAN; METHODOLOGY; MYELOOPTIC NEUROPATHY; PATHOPHYSIOLOGY; PROCEDURES; SECONDARY PREVENTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; NEUROMYELITIS OPTICA; RESEARCH DESIGN; SECONDARY PREVENTION;

EID: 85043602609     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2018.1443077     Document Type: Review

References (91)

1. Jarius S, Wildemann B, Paul F., Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149–164.
2. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
3. Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014;20:843–847.
4. Schmidt F, Zimmermann H, Mikolajczak J, et al. Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2017;11:45–50.
5. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489.
6. Akaishi T, Nakashima I, Misu T, et al. Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica. J Neuroimmunol. 2015;283:70–73.
7. Chavarro VS, Mealy MA, Simpson A, et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3:e286.
8. Elsone L, Townsend T, Mutch K, et al. Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler. 2013;19:475–479.
9. Lana-Peixoto MA, Callegaro D, Talim N, et al. Pathologic yawning in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2014;3:527–532.
10. Penner I-K, Paul F., Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol. 2017;13:662–675.
11. Song Y, Pan L, Fu Y, et al. Sleep abnormality in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2015;2:e94.
12. Graber DJ, Levy M, Kerr D, et al. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008;5:22.
13. Pache F, Wildemann B, Paul F, et al. [Neuromyelitis optica]. Fortschr Neurol Psychiatr. 2017;85:100–114.
14. Wildemann B, Jarius S, Paul F. [Neuromyelitis optica]. Nervenarzt. 2013;84:436–441.
15. Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e134.
16. Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2015;2:e110.
17. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015;21:845–853.
18. Borisow N, Kleiter I, Gahlen A, et al. Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Mult Scler. 2017;23:1092–1103.
19. Collongues N, Marignier R, Jacob A, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler. 2014;20:1086–1094.
20. Krumbholz M, Hofstadt-Van U, Angstwurm OK, et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol. 2015;262:1379–1384.
21. Tenembaum S, Chitnis T, Nakashima I, et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. 2016;87:S59–66.
22. Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016;87:1005–1015.
23. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298:158–162.
24. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59:566–569.
25. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189.
26. Jarius S, Kleiter I, Ruprecht K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016;13:281.
27. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.
28. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279.
29. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71:276–283.
30. Kortvelyessy P, Breu M, Pawlitzki M, et al. ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports. Neurol Neuroimmunol Neuroinflamm. 2017;4:e335.
31. Pache F, Zimmermann H, Mikolajczak J, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282.
32. Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3:e225.
33. Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e257.
34. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2:e62.
35. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68:603–605.
36. Ayzenberg I, Schöllhammer J, Hoepner R, et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol. 2016;263:575–582.
37. Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016;263:25–29.
38. Gelfand JM, Cotter J, Klingman J, et al. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm. 2014;1:e34.
39. Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology. 2012;79:1065–1066.
40. Kira J-I. Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? Mult Scler. 2017;23:1300–1302.
41. Kitley J, Evangelou N, Kuker W, et al. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci. 2014;339:223–225.
42. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239–245.
43. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18:113–115.
44. Yoshii F, Moriya Y, Ohnuki T, et al. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2016;7:53–57.
45. Yamout BI, Beaini S, Zeineddine MM, et al. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Mult. Scler. 2017;23:1297–1300.
46. Stellmann J-P, Krumbholz M, Friede T, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017;88:639–647.
47. Valentino P, Marnetto F, Granieri L, et al. Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study. Neurol Neuroimmunol Neuroinflamm. 2017;4:e317.
48. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73:1342–1348.
49. Tackley G, O’Brien F, Rocha J, et al. Neuromyelitis optica relapses: race and rate, immunosuppression and impairment. Mult Scler Relat Disord. 2016;7:21–25.
50. Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics. 2016;13:70–83.
51. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20:1533–1540.
52. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71:324–330.
53. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1–16.
54. Kim S-H, Huh S-Y, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110–1117.
55. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84:918–921.
56. Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013;84:511–516.
57. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1:180–187.
58. Kim S-H, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011;68:473–479.
59. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128–1133.
60. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65:1443–1448.
61. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U.S.A. 2011;108:3701–3706.
62. Uzawa A, Mori M, Masuda H, et al. Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. Clin Chim Acta. 2017;469:144–149.
63. Bar-Or A, Steinman L, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: part II. Neurol Neuroimmunol Neuroinflamm. 2016;3:e277.
64. Steinman L, Bar-Or A, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: part I. Neurol Neuroimmunol Neuroinflamm. 2016;3:e276.
65. Kremer S, Renard F, Achard S, et al. Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:815–822.
66. Weinshenker BG, Barron G, Behne JM, et al. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. 2015;84:1805–1815.
67. Kelly RJ, Hochsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373:1032–1039.
68. Manthey HD, Woodruff TM, Taylor SM, et al. Complement component 5a (C5a). Int J Biochem Cell Biol. 2009;41:2114–2117.
69. Moskovich O, Fishelson Z. Quantification of complement C5b-9 binding to cells by flow cytometry. Methods Mol Biol. 2014;1100:103–108.
70. Barbour T, Johnson S, Cohney S, et al. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673–2685.
71. Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol. 2013;735:155–172.
72. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450–1461.
73. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112.
74. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130:1194–1205.
75. Jones MV, Fox-Talbot K, Levy M. Evidence for classic complement activity in neuromyelitis optica. Clin Neuropathol. 2014;33:251–252.
76. Paul F. Hope for a rare disease: eculizumab in neuromyelitis optica. Lancet Neurol. 2013;12:529–531.
77. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554–562.
78. McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. Am J Transplant. 2017;17:2481–2484.
79. Zhou Y-Q, Liu Z, Liu Z-H, et al. Interleukin-6: an emerging regulator of pathological pain. J Neuroinflammation. 2016;13:141.
80. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82:1302–1306.
81. Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756–763.
82. Eaneff S, Wang V, Hanger M, et al. Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017;17:116–122.
83. Tackley G, Vecchio D, Hamid S, et al. Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis. J Neurol Neurosurg Psychiatry. 2017;88:165–169.
84. Kong Y, Okoruwa H, Revis J, et al. Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status. J Neurol Sci. 2016;368:84–88.
85. Bacchiega BC, Bacchiega AB, Usnayo MJ, et al. Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study. J Am Heart Assoc. 2017;6.
86. Bennett JL, O’Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e104.
87. Stuve O, Warnke C, Deason K, et al. CD19 as a molecular target in CNS autoimmunity. Acta Neuropathol. 2014;128:177–190.
88. Perumal JS, Kister I, Howard J, et al. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e61.
89. Cree BA, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler. 2016;22:862–872.
90. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
91. Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016;22:511–519.